Online citations, reference lists, and bibliographies.
← Back to Search

I Ntrabody‐based Strategies For Inhibition Of Vascular Endothelial Growth Factor Receptor‐2: Effects On Apoptosis, Cell Growth, And Angiogenesis

Yurong Yang Wheeler, T. Kute, M. Willingham, S. Chen, D. Sane
Published 2003 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
VEGF, an endothelial‐specific mitogen, is an important tumor angiogenesis growth factor. The major receptor for VEGF on endothelial cells is KDR. We hypothesized that an intrabody could bind newly synthesized KDR and block receptor transport to the cell surface, thereby inhibiting important VEGF effects. We expressed a single chain antibody (p3S5) to KDR with or without the endoplasmic reticulum (ER) retention signal (KDEL), using either a plasmid (p3S5‐HAK) or a tet‐off adenoviral system (Ad‐HAK). Plasmid‐mediated expression of the tethered intrabody significantly reduced KDR expression (from 82.5±12.5% to 27.9±13.6% of cells; P<0.01) and thymidine incorporation in successfully transfected cells. Ad‐HAK infection resulted in intrabody expression in >90% of human umbilical vein endothelial cells (HUVECs), producing marked (80%) apoptosis at 48 h postinfection. The intrabody was essential for these effects, as confirmed by inhibiting its expression with doxycycline or by expressing irrelevant genes (lacZ, GFP). Cell death was dependent on KDR, because Ad‐HAK infection of cell lines with minimal or no KDR had little effect on cell viability. Infected HUVECs were unable to form tubes on Engelbreth Holm‐Swarm (EHS) tumor gel matrix. These results demonstrate the potential for development of an intrabody‐based strategy to block angiogenesis and prevent tumor growth.
This paper references
10.1016/0092-8674(88)90553-3
Degradation from the endoplasmic reticulum: Disposing of newly synthesized proteins
J. Lippincott-Schwartz (1988)
Intrabody and immunotoxin-producing cell approaches for cancer gene therapy
Chen (1999)
Technology evaluation: IMC-1C11, ImClone Systems.
S. Hunt (2001)
10.1038/362841A0
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
K. J. Kim (1993)
Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis.
K. Plate (1993)
10.1146/ANNUREV.BIOCHEM.62.1.453
Signaling by Receptor Tyrosine Kinases
W. Fantl (1993)
Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo.
S. Ramakrishnan (1996)
10.1073/PNAS.92.8.3137
Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the alpha subunit of the receptor.
J. H. Richardson (1995)
10.1074/jbc.274.26.18421
Characterization of Vascular Endothelial Cell Growth Factor Interactions with the Kinase Insert Domain-containing Receptor Tyrosine Kinase
S. Cunningham (1999)
10.1073/PNAS.87.7.2628
Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor.
G. Conn (1990)
10.1211/0022357011778232
Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416
J. Sukbuntherng (2001)
A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial.
R. Alvarez (2000)
Vascular endothelial growth factor is a potential tumor angiogenesis factor in human glioma in vivo
K. H. Plate (1992)
10.1006/BBRC.1993.1955
Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody.
S. Kondo (1993)
10.1074/jbc.273.21.13313
Vascular Endothelial Growth Factor Induces Expression of the Antiapoptotic Proteins Bcl-2 and A1 in Vascular Endothelial Cells*
H. Gerber (1998)
Tumor suppressor loci on mouse chromosomes 9 and 16 are lost at distinct stages of tumorigenesis in a transgenic model of islet cell carcinoma.
S. Parangi (1995)
10.1073/PNAS.90.16.7889
Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody.
W. Marasco (1993)
10.1038/353726A0
Peptide-binding specificity of the molecular chaperone BiP
G. Flynn (1991)
10.1006/BBRC.1997.7607
KDEL receptor expression is not coordinatedly up-regulated with ER stress-induced reticuloplasmin expression in HeLa cells.
D. H. Llewellyn (1997)
Prolonged tumor dormancy by prevention of neovascularization in the vitreous.
S. Brem (1976)
10.1074/jbc.273.46.30336
Vascular Endothelial Growth Factor Regulates Endothelial Cell Survival through the Phosphatidylinositol 3′-Kinase/Akt Signal Transduction Pathway
H. Gerber (1998)
Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis.
R. Shaheen (1999)
10.1074/JBC.M101332200
Intracellular Stability of Anti-caspase-3 Intrabodies Determines Efficacy in Retargeting the Antigen*
A. Rajpal (2001)
10.1016/S0002-9440(10)65284-4
Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression.
J. Nör (1999)
10.1016/0006-291X(89)92678-8
Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells.
N. Ferrara (1989)
10.1073/PNAS.95.8.4625
An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells.
G. Siemeister (1998)
10.1016/S0014-5793(01)03101-5
Antigen‐independent selection of stable intracellular single‐chain antibodies
A. Auf der Maur (2001)
10.1172/JCI118370
Targeted tumor killing via an intracellular antibody against erbB-2.
J. Deshane (1995)
10.1074/jbc.274.23.16349
Akt Mediates Cytoprotection of Endothelial Cells by Vascular Endothelial Growth Factor in an Anchorage-dependent Manner*
Y. Fujio (1999)
10.1002/j.1460-2075.1987.tb04803.x
Molecular cloning of the beta‐subunit of human prolyl 4‐hydroxylase. This subunit and protein disulphide isomerase are products of the same gene.
T. Pihlajaniemi (1987)
Vascular permeability factor gene expression in normal and neoplastic human ovaries.
T. Olson (1994)
10.1023/A:1006094117427
Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy
L. Witte (2004)
10.1038/NM1197-1222
Halting angiogenesis suppresses carcinoma cell invasion
M. Skobe (1997)
10.1073/PNAS.94.16.8761
Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal.
L. Benjamin (1997)
The splice variants of vascular endothelial growth factor (VEGF) and their receptors.
C. J. Robinson (2001)
10.1172/JCI116165
Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms.
R. Berkman (1993)
10.1038/367576A0
Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
B. Millauer (1994)
10.1128/JVI.76.3.1475-1487.2002
E4orf6 Variants with Separate Abilities To Augment Adenovirus Replication and Direct Nuclear Localization of the E1B 55-Kilodalton Protein
J. S. Orlando (2002)
10.1006/BBRC.1999.1589
Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells.
J. Tran (1999)
10.1038/sj.gt.3300346
Intrabodies: turning the humoral immune system outside in for intracellular immunization
W. Marasco (1997)
10.1016/0304-419X(90)90014-R
Tumor interactions with the vasculature: angiogenesis and tumor metastasis.
C. Blood (1990)
10.1038/NM0295-149
Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
L. Holmgren (1995)
ERD2 proteins mediate ER retention of the HNEL signal of LRP's receptor-associated protein (RAP).
G. Bu (1997)
10.1016/S0039-6060(96)80120-6
Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer.
K. Anan (1996)
10.1073/PNAS.93.16.8502
Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor.
S. Cheng (1996)
10.1016/0046-8177(95)90119-1
Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer.
L. F. Brown (1995)
10.1093/nar/27.13.2569
Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA
T. J. Parry (1999)
10.1146/ANNUREV.BI.62.070193.002321
Signalling by receptor tyrosine kinases.
W. Fantl (1993)
Vascular endothelial growth factor as a marker of tumor endothelium.
R. Brekken (1998)
10.1038/NM1097-1110
Inactivation of HIV-1 chemokine co-receptor CXCR-4 by a novel intrakine strategy
Ji-Dai Chen (1997)
10.1073/PNAS.97.2.805
Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion.
P. Steinberger (2000)
10.1093/JNCI/87.3.213
Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells.
H. Zhang (1995)
Tumor suppressor loci in mouse chromosome 9 and chromosome 16 are lost at distinct stages of tumorigenesis in a transgenic mouse model of islet cell carcinoma
S. Parangi (1995)
Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway: Requirement for Flk1/KDR activation
H. P. Gerber (1998)
10.1016/0092-8674(87)90086-9
A C-terminal signal prevents secretion of luminal ER proteins
S. Munro (1987)
10.1016/S0022-1759(99)00135-0
Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2.
D. Lu (1999)
10.1002/j.1460-2075.1993.tb05943.x
Mutational analysis of the human KDEL receptor: distinct structural requirements for Golgi retention, ligand binding and retrograde transport.
F. Townsley (1993)
10.1172/JCI5028
Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal.
L. Benjamin (1999)
10.1038/359845A0
Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo
K. Plate (1992)
An antagonistic vascular endothelial growth factor (VEGF) –stimulated receptor autophosphorylation and proliferation of human endothelial cells
G. Siemeister (1998)
Amino acid and cDNA sequence of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor
G. Conn (1990)
10.1200/JCO.2001.19.3.843
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.
M. Gordon (2001)
10.1016/S0022-5347(01)62450-9
Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer.
J. P. Crew (1997)
10.1007/s00109-002-0397-4
The role of VEGF in normal and neoplastic hematopoiesis
H. Gerber (2002)
Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence.
M. Saleh (1996)
10.1007/BF00665960
Vascular permeability factor (VPF, VEGF) in tumor biology
D. Senger (2004)
10.1006/MTHE.2000.0026
Intrakines--evidence for a trans-cellular mechanism of action.
B. Engel (2000)
10.1002/j.1460-2075.1993.tb06164.x
Quality control of ER synthesized proteins: an exposed thiol group as a three‐way switch mediating assembly, retention and degradation.
A. Fra (1993)
10.1073/PNAS.95.18.10820
Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor.
R. Jain (1998)
10.1016/0022-2836(92)91039-R
Sequence of a second human KDEL receptor.
M. Lewis (1992)
10.1073/PNAS.90.19.8915
Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth.
K. Peters (1993)
10.1146/ANNUREV.CB.04.110188.001353
Regulation of protein export from the endoplasmic reticulum.
J. Rose (1988)
10.1038/NM1095-1024
Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity
T. Alon (1995)
10.1016/S0092-8674(00)81881-4
ER Quality Control: The Cytoplasmic Connection
R. Kopito (1997)
10.1038/348162A0
A human homologue of the yeast HDEL receptor
M. Lewis (1990)
10.1073/PNAS.90.22.10705
Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor.
R. Kendall (1993)
Technology evaluation: IMC-1C11
S. Hunt (2001)



This paper is referenced by
10.1158/1535-7163.MCT-05-0174
Human single-domain neutralizing intrabodies directed against Etk kinase: a novel approach to impair cellular transformation
K. Paz (2005)
10.1038/cgt.2016.76
Intrabody targeting vascular endothelial growth factor receptor-2 mediates downregulation of surface localization
E. Alirahimi (2017)
10.1007/978-3-540-33177-3_24
Vascular Endothelial Growth Factor Receptor Antibodies for Anti-Angiogenic Therapy
P. Bohlen (2008)
10.1167/IOVS.06-0419
Flt-1 intraceptor induces the unfolded protein response, apoptotic factors, and regression of murine injury-induced corneal neovascularization.
N. Singh (2006)
10.1586/ecp.10.28
Rationale and development of multispecific antibody drugs
Jijie Gu (2010)
10.4172/2157-7013.1000214
ER Intrabodies: Potent Molecules for Specific Knockdown of Proteins Passingthe ER
Thomas Boldicke (2015)
10.3892/mmr_00000072
Chemically modified siRNA directed against the KDR gene inhibits the proliferation of breast cancer cells.
Yin-lin Ge (2009)
10.1016/J.IMBIO.2008.12.006
Potent inhibition of OKT3-induced T cell proliferation and suppression of CD147 cell surface expression in HeLa cells by scFv-M6-1B9.
Nutjeera Intasai (2008)
10.1111/j.1582-4934.2007.00002.x
Blocking translocation of cell surface molecules from the ER to the cell surface by intracellular antibodies targeted to the ER
T. Böldicke (2007)
10.1007/978-3-540-73259-4_15
Intracellular antibodies (intrabodies) and their therapeutic potential.
A. S. Lo (2008)
10.1016/J.YMTHE.2005.04.003
Intrabody applications in neurological disorders: progress and future prospects.
T. Miller (2005)
Affinity protein based inhibition of cancer related signaling pathways
Erik Vernet (2009)
10.1016/J.JMB.2004.07.054
Development of a human light chain variable domain (V(L)) intracellular antibody specific for the amino terminus of huntingtin via yeast surface display.
David W. Colby (2004)
Isolation, engineering, and characterization of intracellular antibodies specific for the huntingtin protein
David W. Colby (2005)
10.1016/j.jmb.2008.05.047
Organelle-targeted delivery of biological macromolecules using the protein transduction domain: potential applications for Peptide aptamer delivery into the nucleus.
T. Yoshikawa (2008)
10.1021/PR0603349
Nanotools for megaproblems: probing protein misfolding diseases using nanomedicine modus operandi.
V. Uversky (2006)
10.1016/B978-012397632-1/50012-5
CHAPTER 11 – Gene Therapy for CNS Diseases Using Intrabodies
Todd W. Miller (2006)
10.1016/S1359-6446(04)03269-6
Intrabodies: production and promise.
Martin R Stocks (2004)
10.1016/J.CARDIORES.2006.08.005
An anti-major histocompatibility complex class I intrabody protects endothelial cells from an attack by immune mediators.
C. Doebis (2006)
10.3390/antib8040055
Antibody Structure and Function: The Basis for Engineering Therapeutics
M. Chiu (2019)
10.1007/978-3-319-32805-8_5
Recent Advances with ER Targeted Intrabodies.
Andrea L. J. Marschall (2016)
10.1517/14728220903473194
Targeting Pyk2 for therapeutic intervention
C. Lipinski (2010)
Rôle de la protéine tyrosine phosphatase DEP-1 dans la régulation du programmeangiogénique induit par le VEGF
C. Chabot (2010)
10.2741/2152
Protein i: interference at protein level by intrabodies.
J. Manikandan (2007)
Morphological Alterations of Microvasculature and Neoangio-genesis in the Pressure Ulcers Repair in Paraplegics
R. Scelsi (2007)
10.1016/S1525-0016(03)00183-7
Intrabody and intrakine strategies for molecular therapy.
Yurong Yang Wheeler (2003)
10.5772/62103
ER-targeted Intrabodies Mediating Specific In Vivo Knockdown of Transitory Proteins in Comparison to RNAi
Oliver Backhaus (2016)
10.1016/J.JIM.2005.03.007
Novel highly efficient intrabody mediates complete inhibition of cell surface expression of the human vascular endothelial growth factor receptor-2 (VEGFR-2/KDR).
T. Böldicke (2005)
10.1016/J.CONTRACEPTION.2004.12.017
Intraovarian actions of anti-angiogenic agents disrupt periovulatory events during the menstrual cycle in monkeys.
F. Xu (2005)
10.1158/1535-7163.MCT-08-1055
The Pyk2 FERM domain as a target to inhibit glioma migration
J. Loftus (2009)
10.1007/s40259-020-00419-w
Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology
Congcong Zhang (2020)
10.1080/19420862.2015.1076601
Specific in vivo knockdown of protein function by intrabodies
Andrea L. J. Marschall (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar